Johnson & Johnson update
Sign up for myFT Daily Digest and be the first to learn about Johnson & Johnson news.
Johnson & Johnson announced that Joaquin Duato will succeed his mentor Alex Gorsky as CEO, who will step down in early January after holding the position for nearly ten years .
Gorski will serve as executive chairman and will hand over power to his long-time disciple on January 3, marking the end of his more than 30-year career.
He said that after helping the company achieve strong performance in various businesses during his tenure and positioning it as “sustainable success”, now is the right time to resign “for family health reasons.”
Recently, Gorsky was forced to resolve manufacturing issues that harmed Johnson & Johnson’s consumer health business. The company’s So-called role inside U.S. opioid epidemic And litigation related to its talc products.
Duato has also worked in the company for more than 30 years and is currently the vice chairman of Johnson & Johnson’s executive committee. Since 2018, he has been in charge of the company’s consumer business, global supply chain, technology, and health and wellness team in addition to his responsibilities as the head of Johnson & Johnson’s pharmaceutical division. Recently, he was responsible for overseeing Johnson & Johnson’s response to the Covid-19 pandemic.
The latest coronavirus news
Pay attention to the on-site report and analysis of the British “Financial Times” on the global epidemic and the rapidly evolving economic crisis here.
Gorski said he was “full of confidence” in Duato’s leadership of Johnson & Johnson, who has U.S. and Spanish citizenship. “During our cooperation for more than 25 years, he has always shown a passion for solving complex medical and business challenges,” he said in a statement.
Given the highly contagious variants that have erupted globally and the recent debate about necessity, guiding the company through the pandemic will remain Duato’s top priority. Booster shooting.
Although Johnson & Johnson’s stock price is close to record highs, its efforts to win public trust during the public health crisis have been more bumpy than other drugmakers.
In the first few months of the global vaccine launch, reports of “rare and severe” thrombosis in some recipients prompted several health agencies around the world to at least pause Use the company’s single injection dose.In addition, a batch of vaccines produced at a plant in Baltimore Factory error.